Nordion Inc (NDN.TO) Buy, Sell or Hold

Nordion Inc (NDN.TO)

0.00

-0.00 (0.00%)

4 watching

DON'T BUY

As a model price of $23.24 which is a 16% differential. Thinks the top on this is $21.55. More exciting things out there.

HOLD

Has a lot of interesting assets that are cheap. Thinks new management now has a mandate to shake things up. Thinks there will be some spin offs.

HOLD

Has been base building since 2001. All you want now is for the stock to hit around $20 which would be a signal for the next leg. If the stock drops below $17, Sell.

DON'T BUY

They have management changeover, so the juries out. Until you see what the new CEO is going to do and what direction the company is going to move, the stock won't do much.

HOLD

His Fair Market Value is up around $27/28 and the stock looks like it is basing at about 1.5 X book and has been for some little while.

DON'T BUY

The key multiples are trading below average and charts don't look too bad, so there may not be much downside. On the other hand, there's nothing really clicking there to generate any decent earnings growth.

WATCH

On their watch list. Has been a real dog and shareholders are unhappy. Has been very complicated to analyze because it has so many different businesses.

HOLD

Very interesting at this level. Break up value would be towards $19. Management has been questionable in terms of materializing value for shareholders. Has been a chronic underperformer on an operating basis and stock. Could be a trust.

DON'T BUY

Sold his holdings 18 months 2 years ago. There was always something that wasn't working. There are nice things in there and if they ever got it sorted out, it would be a good company and a fairly profitable investment. Just reported more disappointing numbers.

DON'T BUY

Just reported a disappointing quarter. Wasn't able to mitigate the impact of the 20% fee cut that B.C. put through. Theoretically this should be a great stock as the demographics are very positive. At current multiples it is not an attractive investment.

DON'T BUY

Has historically struggled in spite of a variety of different managers being on the scene. Ranks neutral at 347 of the data base model. Year over year sales is bland at 4% although earnings is up 15%.

WAIT

Have not invested their free cash flow wisely. Have been making changes to get more focus on capital employed. Wait to see who the new CEO will be and their focus.

BUY

Has been weak, but feels it is fine now. This should be held with a basket of similar health related stocks.

DON'T BUY

Has been a disappointment over the last 2/3 years. Prefers US medical services.

HOLD

Have not been satisfied with the stock. Throws off a lot of free cash flow which has not been invested wisely. Starting to focus on return of capital. Has had some good management changes.

Showing 16 to 30 of 229 entries

Most Recent Experts

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Bryn Talkington

Requisite Capital Management

Shannon Saccocia, CIO, Boston Private

Boston Private

David Burrows

Barometer Capital Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Nordion Inc (NDN.TO)